Alnylam Pharmaceuticals, Inc. (ALNY) Market Cap

Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalization of $43.11B, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Exchange: NASDAQ Global Select
Headquarters: Cambridge, MA, US
Website: https://www.alnylam.com

Loading company profile...

Expand full investment commentary ▼

📘 ALNYLAM PHARMACEUTICALS INC (ALNY) — Investment Overview

🧩 Business Model Overview

Alnylam Pharmaceuticals Inc. is a pioneering biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. RNAi is a novel biological mechanism that enables the selective silencing of genes responsible for causing or worsening diseases. Alnylam’s core strategy centers on leveraging this approach to address significant unmet medical needs, primarily within rare genetic, cardio-metabolic, hepatic infectious, and central nervous system disorders. The company operates with a fully integrated model, encompassing R&D, clinical development, regulatory affairs, manufacturing, and commercial activities. By advancing both proprietary and partnered pipeline programs, Alnylam aims to sustain a diversified portfolio that can deliver multiple revenue streams while mitigating single-asset risk. Partnerships with pharmaceutical majors expand reach and capabilities, while direct commercialization in key geographies supports control over pricing and patient engagement.

💰 Revenue Streams & Monetisation Model

Alnylam generates revenue from a combination of product sales, royalties, and collaboration or licensing agreements. Its wholly-owned and co-commercialized products, launched globally for rare diseases, constitute the primary source of revenue. These commercial therapies typically command orphan drug pricing due to the limited patient populations and high unmet clinical need they address. A secondary stream derives from strategic alliances. The company earns milestone payments and royalties by out-licensing its technology or collaborative pipeline assets, leveraging partners’ commercial infrastructure in regions or indications outside Alnylam’s immediate reach. This hybrid approach provides both near-term cash flow through non-dilutive funding and long-term upside via royalty participation in partner-led therapies. Additionally, Alnylam benefits from research funding and option fees as pharmaceutical collaborators advance preclinical and clinical candidates. As the portfolio expands, the company’s model is increasingly weighted toward direct product revenues while maintaining supplemental collaboration income for reinvestment in innovation.

🧠 Competitive Advantages & Market Positioning

Alnylam’s chief competitive advantage lies in its first-mover status and deep expertise in RNAi science. The company owns foundational intellectual property covering both chemical modifications and delivery technologies critical for the safe and effective use of RNAi therapeutics in humans. Decades of investment and successful translation of RNAi from a scientific concept to approved products have established significant entry barriers. Proprietary delivery systems, including GalNAc-conjugate platforms, underpin much of the clinical pipeline, facilitating efficient targeting of disease-causing genes in the liver and beyond. This technology differentiates Alnylam's candidates in terms of safety, dosing convenience, and specificity. The company also enjoys an established commercial infrastructure in key strategic markets for rare disease therapies, including the United States and select European countries. Long-term relationships with patients, providers, and advocacy groups further entrench its position in the rare and ultra-rare disease space. Finally, Alnylam’s scientific credibility and success in securing regulatory approvals have enabled robust partnerships with major pharmaceutical and biotechnology peers, giving the firm expanded reach, shared risk, and non-dilutive capital.

🚀 Multi-Year Growth Drivers

Several secular and company-specific trends are poised to drive multi-year growth for Alnylam: - **Expanding Label Indications for Approved Products:** As Alnylam’s initial commercial therapies are studied for additional indications and earlier lines of treatment, the addressable patient population and lifetime value of each asset increase. - **Pipeline Expansion:** A robust internal pipeline targeting multiple rare and prevalent diseases presents significant opportunity for organic growth. Successful proof-of-concept for RNAi in new organ systems and disease areas could unlock vast new markets. - **Advancements in Delivery Technology:** Improving delivery systems may enable targeting of tissues beyond the liver, thereby broadening the clinical impact and market potential of RNAi therapeutics. - **Geographic Expansion:** Regulatory approvals and commercial launches in additional international markets represent an important growth lever, with strategies tailored to the pricing and reimbursement dynamics of each region. - **Strategic Partnerships and Licensing:** Existing and new alliances can accelerate pipeline progress, provide non-dilutive capital, and increase global royalty streams. - **Rising Adoption of Genetic Medicines:** Growing physician familiarity and payer acceptance of RNAi, in part due to increased real-world evidence and outcomes data, underpin greater adoption and penetration over time.

⚠ Risk Factors to Monitor

Alnylam faces a range of risks inherent to the biotech sector and its chosen strategies: - **Regulatory and Clinical Risk:** The RNAi field is relatively nascent, and success in one indication or product class does not guarantee broader applicability. Unfavorable clinical trial results or regulatory setbacks could materially impact growth expectations. - **Intellectual Property Challenges:** Alnylam’s business relies on a strong patent estate. Loss of exclusivity, patent challenges, or competing technologies could erode its competitiveness. - **Commercialization Risk:** Slow physician adoption, reimbursement challenges, or competition from alternative treatment modalities (such as gene editing) could limit the uptake of approved products. Given the high pricing typical in rare diseases, policy shifts or increased payer scrutiny pose a relevant challenge. - **Manufacturing and Supply Chain Complexity:** Specialized therapies require precise manufacturing processes and robust cold-chain logistics, creating operational risks, particularly as the product portfolio and patient base scale. - **Dependence on Partnerships:** The company is partially reliant on its partners for co-development, regulatory submissions, commercialization, and geographic expansion, introducing execution and alignment risk. - **Concentration of Revenue:** Early in its lifecycle, Alnylam’s reliance on a limited number of assets and indications results in revenue concentration risk.

📊 Valuation & Market View

Market participants tend to value Alnylam using a combination of pipeline-adjusted (risk-weighted) discounted cash flow models and sum-of-the-parts approaches that reflect both current product revenues and optionality from the extensive clinical pipeline. These analyses incorporate assumptions regarding the probability of technical and regulatory success across each pipeline asset, market penetration trajectories, and durability of exclusivity. Given the potential for rapid multi-year revenue growth from newly launched products and pipeline progression, Alnylam commonly trades at multiples (e.g., price-to-sales, enterprise-value-to-sales) that exceed those of mature pharmaceutical peers but are in line with innovation-driven biotech firms. Investors weigh the company’s demonstrated execution in the RNAi space and growing commercial footprint against the high cost base and ongoing need for R&D reinvestment. Sell-side sentiment often reflects a mix of optimism about the long-term potential for RNAi medicines to disrupt multiple therapeutic categories and caution around execution risks, reimbursement policy, and the timing of key clinical data readouts.

🔍 Investment Takeaway

Alnylam Pharmaceuticals represents a compelling, innovation-led investment opportunity within the genetic medicines sector. Its leadership in RNAi, differentiated by both technological prowess and commercial execution, supports the foundation for long-term value creation as the field matures. The company's diversified pipeline, proven track record in regulatory success, and hybrid business model provide multiple avenues for sustainable revenue growth and strategic flexibility. Nevertheless, the typical risks of early commercialization, pipeline execution, dependency on a handful of products, and the evolving reimbursement landscape must be considered. Diligent monitoring of clinical progress, regulatory filings, and competitive developments remains paramount. For investors seeking exposure to transformative therapies and high-growth biotech, Alnylam offers attractive exposure, albeit with the volatility intrinsic to innovation-driven healthcare equities.

⚠ AI-generated — informational only. Validate using filings before investing.

📢 Show latest earnings summary

ALNY Q4 2025 Earnings Summary

Overall summary: Alnylam delivered a breakout year, with Q4 momentum and full-year 2025 performance exceeding expectations, driven by the successful U.S. launch of Amvuttra in ATTR cardiomyopathy. The company achieved GAAP and non-GAAP profitability and outlined ambitious 2030 goals anchored in TTR leadership and platform-led innovation. While near-term headwinds include gross-to-net dynamics, Germany pricing impacts, and royalty-driven margin pressure, management’s tone was confident, supported by strong access, under-penetrated market opportunity, expanding international launches, and a robust pipeline with multiple potential blockbuster catalysts into 2028–2030.

Growth

  • Full-year 2025 combined net product revenues nearly $3B, up 81% YoY
  • Q4 2025 combined net product revenues $995M, +121% YoY and +17% QoQ
  • TTR franchise Q4 net revenues $858M, +18% QoQ and +151% YoY; strong U.S. demand
  • Rare disease franchise Q4 revenue $136M, +26% YoY; GIVLAARI + OXLUMO reached ~$500M in 2025
  • Six Alnylam-invented medicines on market generating several billion dollars annually

Business development

  • Launched Amvuttra for ATTR cardiomyopathy; additional ex-U.S. launches expected in 2026 pending pricing/reimbursement
  • Aligned Germany pricing for Amvuttra cardiomyopathy to access larger market (near-term Q1 revenue headwind)
  • Introduced Cyrillis enzymatic ligation RNAi manufacturing platform to expand capacity and reduce COGS
  • Five new partner-led programs entered the clinic in 2025; Regeneron plans U.S. submission for cemdisiran in gMG in Q1 2026 with potential approval late 2026/early 2027

Financials

  • FY25 total global net product revenues nearly $3B, >$800M above initial guidance
  • FY25 collaboration revenue $553M (+8% YoY), including $300M milestone from ZENITH Phase 3 first patient
  • FY25 royalty revenue $104M (+90% YoY) driven by higher Novartis Leqvio sales
  • FY25 gross margin on product sales 77% (down 4 pts YoY) due to higher Amvuttra royalties payable to Sanofi
  • FY25 non-GAAP R&D approx. $1.2B (+17% YoY) reflecting three Phase 3 initiations
  • FY25 non-GAAP SG&A approx. $1.0B (+22% YoY) supporting Amvuttra launch
  • FY25 non-GAAP operating income $850M (up $755M YoY)
  • GAAP and non-GAAP profitability achieved in Q4 and full-year 2025; profitability expected to be sustained

Capital & funding

  • Expect to sustain GAAP profitability going forward
  • Plan to invest ~30% of revenues in non-GAAP R&D through 2030 to accelerate internal and selective external innovation
  • Target non-GAAP operating margin of ~30% through 2030; potential mid-40s post-2030 if nuceresiran approved (no royalties)

Operations & strategy

  • Alnylam 2030 goals centered on global TTR leadership, sustainable innovation, and disciplined scaling
  • TTR strategy: aspire to lead category in revenue; nuceresiran targeted launches in 2028 (polyneuropathy) and 2030 (cardiomyopathy)
  • Innovation goals: deliver 2+ blockbuster medicines beyond TTR, expand RNAi delivery to 10 tissues, build 40+ clinical programs by 2030
  • ATTR-CM U.S. launch focus on first-line use and stabilizer progressors; >90% payers offer first-line coverage, most patients zero OOP, ~90% within 10 miles of care
  • Investing in education, diagnosis enablement, and evidence generation to expand category

Market & outlook

  • ATTR-CM market remains under-penetrated despite ~40% volume CAGR over six years; early data show Amvuttra approaching tafamidis share of new starts by the second quarter post-launch
  • Ex-U.S. momentum building; launches expected across additional markets in 2026
  • Japan ~6 months into launch tracking in line with leading analogs; hATTR polyneuropathy business remains resilient despite competition
  • Key pipeline timelines: ZENITH outcomes trial (~11,000 pts) positions zalesiran for potential 2030 launch; TRITON-CM (~1,200 pts) and TRITON-PN support nuceresiran launches in 2030 and 2028, respectively
  • 2026 milestones: complete CAPRICORN I Phase 2 enrollment (CAA); initiate three Phase 2s (incl. ALN-4324 in T2D); 2H readouts for ALN-6400 (Phase 1/2) and Phase 1 data for ALN-HTT02 and ACVR1C

Risks & headwinds

  • Q4 U.S. TTR growth partially offset by higher gross-to-net deductions and unfavorable inventory channel impact
  • Germany price alignment to cause modest near-term TTR revenue impact in Q1 2026
  • Gross margin pressure from higher Amvuttra royalties payable to Sanofi
  • ATTR-CM launch still early; ongoing execution needed to drive diagnosis and adoption
  • Competitive landscape (e.g., tafamidis; competition in hATTR polyneuropathy) persists
  • Event-driven outcomes trials (ZENITH, TRITON-CM) entail timing and results risk for 2030 launches

Sentiment: positive

📊 Alnylam Pharmaceuticals, Inc. (ALNY) — AI Scoring Summary

📊 AI Stock Rating — Summary

Alnylam Pharmaceuticals reported a quarterly revenue of approximately $1.1 billion with a net income of $186 million, resulting in an EPS of $1.41. The net margin stands at 17%, reflecting efficiency in converting revenue to profit. The free cash flow of $140 million, derived from an operating cash flow of $164 million and capex of $23 million, highlights a positive cash generation trend. Year-over-year revenue exhibits healthy growth, though precise figures weren't provided for comparison. The balance sheet shows total assets of $4.97 billion against liabilities of $4.18 billion, indicating moderate leverage with a net debt of $1.31 billion. Despite no dividends or share buybacks, Alnylam maintains financial flexibility. Analyst consensus provides a positive outlook with a median target price of $483, suggesting potential for valuation upside. Current data points to sturdy revenue growth, sound profitability, and proactive cash flow management, balanced by higher leverage levels. Alnylam's robust fundamentals and positive analyst sentiment underline a favorable position within the pharmaceutical sector.

AI Score Breakdown

Revenue Growth — Score: 7/10

Revenue reflects substantial growth. Main drivers include effective product development and market expansion. Stability in revenue streams is evident, albeit more context on yearly growth is needed.

Profitability — Score: 8/10

Net margin of 17% and EPS of $1.41 point to solid profitability. Operational efficiencies are likely optimized, enhancing EPS.

Cash Flow Quality — Score: 6/10

FCF is positive and stable at $140 million. No dividends or stock repurchases indicate focus on reinvestment and growth. Liquidity remains robust.

Leverage & Balance Sheet — Score: 5/10

A net debt level of $1.31 billion raises leverage concerns. However, a solid equity base and asset level provide some financial resilience.

Shareholder Returns — Score: 5/10

No dividends or buybacks were executed, which may limit immediate shareholder returns, yet offers flexibility for strategic initiatives.

Analyst Sentiment & Valuation — Score: 8/10

High median target price of $483 suggests a favorable outlook. Analyst confidence implies undervaluation potential amid strong performance.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

RMD logo

RESMED INC (RMD)

Healthcare

$37.57B

GEHC logo

GE HEALTHCARE TECHNOLOGIES INC (GEHC)

Healthcare

$36.53B

IDXX logo

IDEXX LABORATORIES INC (IDXX)

Healthcare

$50.84B

EW logo

EDWARDS LIFESCIENCES CORP (EW)

Healthcare

$51.18B

A logo

AGILENT TECHNOLOGIES INC (A)

Healthcare

$33.50B

CAH logo

CARDINAL HEALTH INC (CAH)

Healthcare

$54.09B